reason report
ho flat sale ex otezla enough get excit
result beat consensu revenu ep
estim provid initi guidanc suggest cautiou
outlook year ahead margin us volum growth
exist core product off-set continu price pressur addit
otezla provid one time boost growth effect like
short live overal major surpris compani
legaci product continu erod face continu gener
biosimilar competit despit perform compani
emerg product continu price pressur suggest
reliant otezla early-stag oncolog pipelin provid
meaning acceler compani growth trajectori net
result guidanc commentari make modest
chang revenu earn forecast maintain
current market perform rate stock increas
target price base peer compani multipl compani
cash flow share count reduct fail see suffici reason
get excit stock recent valuat
averag dcf price-to-earnings p/sale
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million dilut non-gaap ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target inc stock rate market perform
one first gener pioneer biopharmaceut industri succeed
basi build three massiv revenu pillar legaci product era three
product franchis epo epogen aranesp gcsf neulasta enbrel
face array brand gener competitor mean associ
revenu total like steadili declin offset outlook
number recent develop acquir product growth profit potenti
view unlik match legaci brand least mani year amgen
manag respond challeng restructur compani expens base
initi dividend lever compani balanc sheet cash trap off-shore
gener make legaci product compar peer regard
defens stock also one lack explos upsid potenti typic associ
breakthrough rapidli grow biotherapeut stock
revenu larg without major surpris total revenu
higher estim higher consensu product sale declin
yoy increas qoq higher consensu higher
estim yoy total product sale volum growth off-set declin net sell
price sale grew yoy driven volum growth off-set
enbrel sale stronger consensu line estim
yoy growth enbrel sale mainli driven favor chang account estim
higher net sell price off-set declin volum inventori
build-up neulasta sale continu declin eros yoy qoq driven
biosimilar competit neg impact volum net sell price global neulasta
sale consensu estim indic
exit share long-act segment onpro exit share
sensipar sale increment lower collaps earli part due
continu gener competit revenu declin yoy moder
sequenti basi qoq declin
hematology/oncolog product sale grew yoy rel flat
sequenti basi driven unit volum growth includ vectibix nplate
xgeva kyproli blincyto imlyg sale report
posit momentum biosimilar product continu kanjinti sale
increas qoq mvasi sale increas qoq amgevita grow qoq
newer product aimovig sale grew yoy qoq significantli miss
estim consensu howev yearli declin driven
unfavor chang account estim follow adjust aimovig would
grown yoy indic paid demand addit
increas coverag live repatha came estim
consensu sale repres yoy growth driven
increas unit volum off-set inventori decreas although net
sell price declin yoy manag indic price appear remain rel
stabl qoq even sale increas repres sequenti growth
suggest product annual primarili driven success
japanes launch major sale continu occur outsid us us
row product aimovig repatha even continu key
contributor top line growth manag seem excit addit otezla
sale reflect acquisit close novemb guid
toward light rel subsequ quarter indic would consist
histor sale pattern product expect time acquisit otezla
seem like provid almost net revenu growth
financi guidanc light top bottom line manag provid initi
financi guidanc revenu guidanc rang
estim slightli consensu midpoint adjust ep guidanc
lower estim consensu adjust tax rate
guidanc lower consensu estim
compani issu capital-expenditure guidanc higher estim
slightli consensu estim overal guidanc suggest
cautiou effect signal almost top line growth
like come recent acquir otezla
pipelin enthusiasm center around otezla pipelin commentari primarili
revolv around compani continu acceler clinic develop
asset expect initi clinic data phase nsclc monotherapi follow
earli complet enrol addit readout includ updat phase monotherapi
data multipl solid tumor type initi phase data combin keytruda nsclc
expect readout import event given concern treatment durabl
potenti greater efficaci combin checkpoint inhibitor addit
compani continu enrol patient multipl on-going studi includ monotherapi
studi treatment-nav nsclc patient phase monotherapi studi phase
combin studi mek inhibitor nsclc continu remain optimist
prospect otezla compani provid updat indic april
pdufa scalp psoriasi phase data readout expect mid-year mild-to-moder
psoriasi compani expect data readout two on-going registr studi
tezepelumab sever uncontrol asthma omecamtiv mecarbil heart failur
reduc eject fraction hfref compani mute commentari suggest
expect rel low program compani also suggest
make progress on-going develop bite program expect disclos first in-
human data readout bcma hle bite sometim year
price target inc base averag three approach
believ reason basi valu stock today approach simpl price
earn multipl larg cap us eu larg cap biopharma stock celg
sni rhhbi gsk nv price sale multipl larg cap
biotechnolog pharma compani novo nv
discount cash flow dcf use rel multipl larg cap biopharma compani
ep appli ep estim give one year
futur valu use establish larg cap futur revenu multipl sale
appli revenu forecast give futur valu final
dcf valuat base current outlook compani exist product
probability-weight revenu contribut late-stag pipelin program discount
compani wacc give fair valu today averag three
approach give price target
risk view outlook valuat includ major chang label
price reimburs coverag compani legaci product failur
compani growth portfolio achiev futur sale forecast risk includ develop
delay disappoint earlier stage pipelin asset earlier signific eros
compani legaci product biosimilar innov competit shortfal
compani effort improv oper margin would also materi affect outlook
valuat would larg dilut acquisit therapeut area platform
sale
interest expens incom net
non-gaap incom tax
share count period dilut
guidanc
svb leerink research compani file zack factset consensu
svb leerink research compani file zack factset consensu
brand chemic
type event
event trial detail
date known
up/down
expect
phase result hfref
initi phase trial patient elev
initi phase result combin
mild moder
phase result mild moder psoriasi
proof concept data
svb leerink llc research compani file
million
corp partner revenue incl royalti
po probabl success fda approv
sbv leerink llc research compani file
million
sale
total expens exclud revenue sharing/incl sg
 total revenu
sg total revenu excl profit share
profit share total revenu
sbv leerink llc research compani file
analysi stock price svb leerink target
method model larg cap healthcar growth stock ep multipl ep
appli amgen ep
svb leerink updat ep estim
current averag ep multipl consensu ep compar slow
grow us eu larg cap biopharma stock
impli target price ep
revenu multipl appli svb leerink revenu forecast
svb leerink updat revenu estim
current averag larg cap biopharma multipl revenu
impli valu fy revenu
impli target price revenu use us biopharma comp
method dcf adjust debt declin flow
stabl termin cash flow growth discount wacc
present valu flow termin valu
averag method
svb leerink llc research compani file factset
